These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 28766727)

  • 1. Ethnic disparities in progression to advanced liver disease and overall survival in patients with chronic hepatitis C: impact of a sustained virological response.
    Le AK; Zhao C; Hoang JK; Tran SA; Chang CY; Jin M; Nguyen NH; Yasukawa LA; Zhang JQ; Weber SC; Garcia G; Nguyen MH
    Aliment Pharmacol Ther; 2017 Sep; 46(6):605-616. PubMed ID: 28766727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late development of hepatocellular carcinoma after viral clearance in patients with chronic hepatitis C: A need for continual surveillance.
    Tong MJ; Theodoro CF; Salvo RT
    J Dig Dis; 2018 Jul; 19(7):411-420. PubMed ID: 29889353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
    J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology and outcomes of hepatitis C infection in elderly US Veterans.
    El-Serag HB; Kramer J; Duan Z; Kanwal F
    J Viral Hepat; 2016 Sep; 23(9):687-96. PubMed ID: 27040447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
    van der Meer AJ; Feld JJ; Hofer H; Almasio PL; Calvaruso V; Fernández-Rodríguez CM; Aleman S; Ganne-Carrié N; D'Ambrosio R; Pol S; Trapero-Marugan M; Maan R; Moreno-Otero R; Mallet V; Hultcrantz R; Weiland O; Rutter K; Di Marco V; Alonso S; Bruno S; Colombo M; de Knegt RJ; Veldt BJ; Hansen BE; Janssen HLA
    J Hepatol; 2017 Mar; 66(3):485-493. PubMed ID: 27780714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response.
    Kim GA; Han S; Kim HD; An J; Lim YS
    J Viral Hepat; 2017 Nov; 24(11):990-997. PubMed ID: 28499070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of chronic hepatitis C patients treated with interferon-alpha: risk of cirrhosis and hepatocellular carcinoma in a single center over 10 years.
    Lee HJ; Yeon JE; Yoon EL; Suh SJ; Kang K; Kim HR; Kang SH; Yoo YJ; Je J; Kim JH; Seo YS; Yim HJ; Byun KS
    Intervirology; 2015; 58(1):14-21. PubMed ID: 25592614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy.
    Wang JH; Yen YH; Yao CC; Hung CH; Chen CH; Hu TH; Lee CM; Lu SN
    Liver Int; 2016 Dec; 36(12):1793-1799. PubMed ID: 27254286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C.
    Hedenstierna M; Nangarhari A; Weiland O; Aleman S
    Clin Infect Dis; 2016 Sep; 63(6):723-9. PubMed ID: 27282709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication.
    Huang CF; Yeh ML; Tsai PC; Hsieh MH; Yang HL; Hsieh MY; Yang JF; Lin ZY; Chen SC; Wang LY; Dai CY; Huang JF; Chuang WL; Yu ML
    J Hepatol; 2014 Jul; 61(1):67-74. PubMed ID: 24613362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
    Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
    Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance.
    Huang CF; Yeh ML; Huang CI; Lin YJ; Tsai PC; Lin ZY; Chan SY; Chen SC; Yang HI; Huang JF; Lu SN; Dai CY; Jen CL; Yuan Y; L'Italien G; Wang LY; Lee MH; Yu ML; Chuang WL; Chen CJ
    Oncotarget; 2017 Jul; 8(27):43925-43933. PubMed ID: 28159934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response.
    Cordero-Ruiz P; Carmona-Soria I; Rodríguez-Téllez M; Caunedo-Alvarez A; Quezada-Pacheco RH; Flores-Cucho A; Romero-Gómez M; Vilches-Arenas Á
    Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):792-799. PubMed ID: 28445251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antivirals.
    Huang CF; Yeh ML; Huang CI; Liang PC; Lin YH; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL; Yu ML
    Hepatol Int; 2018 Nov; 12(6):544-551. PubMed ID: 30426395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onset diabetes: a nation-wide cohort study.
    Huang YW; Wang TC; Yang SS; Lin SY; Fu SC; Hu JT; Liu CJ; Kao JH; Chen DS
    Aliment Pharmacol Ther; 2015 Oct; 42(7):902-11. PubMed ID: 26211742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index.
    Lee K; Sinn DH; Gwak GY; Cho HC; Jung SH; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Gut Liver; 2016 Sep; 10(5):796-802. PubMed ID: 27114418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.
    Kanwal F; Kramer J; Asch SM; Chayanupatkul M; Cao Y; El-Serag HB
    Gastroenterology; 2017 Oct; 153(4):996-1005.e1. PubMed ID: 28642197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors of unfavorable prognosis of chronic hepatitis C.
    Shchanitcyna SE; Burnevich EZ; Nikulkina EN; Filatova AL; Мoiseev SV; Мukhin NA
    Ter Arkh; 2019 Mar; 91(2):59-66. PubMed ID: 31094173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis.
    N'Kontchou G; Paries J; Htar MT; Ganne-Carrie N; Costentin L; Grando-Lemaire V; Trinchet JC; Beaugrand M
    Clin Gastroenterol Hepatol; 2006 Aug; 4(8):1062-8. PubMed ID: 16844421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of ethnic influence in the application of a hepatocellular carcinoma predictive model for chronic hepatitis C.
    Wei MT; Le MH; Landis C; Trinh H; Wong G; Le A; Zhang J; Cheung R; Nguyen MH
    J Med Virol; 2021 Nov; 93(11):6257-6266. PubMed ID: 34219250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.